Literature DB >> 15705142

Benefits and challenges brought by improved results from in vitro fertilization.

R P S Jansen1.   

Abstract

Abstract In vitro fertilization (IVF), in which preimplantation-stage embryos are produced after ovarian stimulation and retrieval of preovulatory oocytes, now accounts for almost 2% of all births in Australia. For clinics performing in the top quartile of national results, the chance of a live birth for a woman under 35 years from one round of egg retrieval and IVF treatment is greater than 50%, albeit still with a greater than 20% risk of twins or higher order multiple pregnancy. Similar or better live birth rates are now obtainable with the elective transfer of a single embryo at the stage of blastocyst (5-6 days in culture), a policy that if adopted for younger women can reduce the risk of twins in a clinic to less than 15%. Current developments centre around improvements to embryo culture and the testing of embryos for chromosomal normality and other genetic and epigenetic variables before transfer, made possible by licences for embryo research protocols now being issued under the Commonwealth's Research Involving Human Embryos Act 2002.

Entities:  

Mesh:

Year:  2005        PMID: 15705142     DOI: 10.1111/j.1445-5994.2004.00759.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  2 in total

1.  Deep phenotyping to predict live birth outcomes in in vitro fertilization.

Authors:  Prajna Banerjee; Bokyung Choi; Lora K Shahine; Sunny H Jun; Kathleen O'Leary; Ruth B Lathi; Lynn M Westphal; Wing H Wong; Mylene W M Yao
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

2.  Single blastocyst transfer after ICSI from ejaculate spermatozoa, percutaneous epididymal sperm aspiration (PESA) or testicular sperm extraction (TESE).

Authors:  Staffan Nilsson; Urban Waldenström; Ann-Britt Engström; Dan Hellberg
Journal:  J Assist Reprod Genet       Date:  2007-02-21       Impact factor: 3.412

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.